 Iovance Biotherapeutics Inc NASDAQ: IOVA has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer mNSCLC enrolled in Cohort 3B of the basket study IOV-COM-202. The results demonstrate the feasibility of LN-145, a tumor-infiltrating lymphocyte TIL cell therapy in heavily pre-treated patients. 